BioStock: Follicum comments on patent notice for diabetes candidate
Follicum’s diabetes project took a big leap forward last Friday with a preliminary patent approval from the European Patent Office regarding the company’s diabetes peptides. BioStock contacted CEO Jan Alenfall to find out more about the project, the patent approval, and how the company intends to position its candidate in the extensive range of diabetes treatments.
Read the interview with Jan Alenfall at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se